BLOOD THINNER PRADAXA TARGET OF MASS CLAIM SUITS LEGAL CASES

USATODAY REPORTS BLOOD THINNER PRADAXA TARGET OF MASS CLAIMS SUITS LEGAL CASES
A recent USAToday story entitled “BLOOD THINNER PRADAXA TARGET OF MASS CLAIMS SUITS” touches on why there are a growing number of lawsuits against the manufacturer, BOEHRINGER INGELHEIM.

PRADAXA BLOOD THINNER TARGET OF MASS CLAIMS LEGAL CASES

The story originally appeared in THE TENESSEAN and provided a local story based upon a number of residents seeking redress for injuries.

As noted below and elsewhere on PRADAXACASES.com there is significantly more to the story than most casual observers learn. The short history of the novel anti-coagulant has raised International concerns over uncontrollable bleeding events resulting in deaths, disability or extended hospital admissions. Aggressive marketing of the alternative blood thinner and care free comparisons to WARFARIN and COUMADIN may have secured a significant marketshare, in less than 2 years, for the pills. However, some patients and families have sought out legal help to answer questions over injuries and deaths.

ISMP CONFIRMS 542 DEATHS LINKED TO PRADAXA WITH MORE ADVERSE EVENTS REPORTED IN 2011.

As illustrated in posts below, as well as the graphic above, lawyers and families are not the only  people to question the safety of the pills. The ISMP has analyzed FDA’s data and raised serious questions about dosing and the potential for overdosing of patients. Watchdog groups, victims, survivors and their families may not have headed off PRADAXA becoming a Blockbuster, but they are at the forefront of obtaining answers and safeguarding others.

FREE CASE EVALUATIONS ARE AVAILABLE FROM THS SPONSOR OF THIS SITE THROUGH USE OF THE CONTACT FORM BELOW.

PRADAXA SALES CLIFF - LAWSUIT UPDATE JULY 2012.

PRADAXA SALES CLIFF - LAWSUIT UPDATE JULY 2012.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>